Global Microbubbles/Ultrasound Contrast Agents Market

Microbubbles/Ultrasound Contrast Agents Market Size, Share, Growth Analysis, By Disease Area(Cardio-vascular, Abdominal, Others), By Application(Diagnostic imaging, Drug delivery, Others), By End Use(Diagnostic centers, Hospitals, Others), By Region(North America, Europe, Asia-Pacific, Latin America), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35H2055 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 119 | Figures: 78

Microbubbles/Ultrasound Contrast Agents Market Competitive Landscape

The major players covered in the microbubble contrast media market , while GE Healthcare is committed to providing a broad comprehensive portfolio of CM products that help meet your patient and procedural needs across a multitude of modalities.

Top Players Company Profiles

  • General Electric Company
  • Bracco Imaging S.p.A.
  • Lantheus Holdings, Inc.
  • Daiichi Sankyo Company, Limited
  • Bayer AG
  • Fujifilm Holdings Corporation
  • Sanofi S.A.
  • Siemens Healthineers AG
  • Guerbet Group
  • nanoPET Pharma GmbH
  • MBI Co., Ltd.
  • Trivitron Healthcare
  • Unilife Corporation
  • PTW Freiburg GmbH
  • Esaote SpA
  • Mindray Medical International Limited
  • Samsung Electronics Co., Ltd.
  • Shimadzu Corporation
  • Philips Healthcare
  • Canon Medical Systems Corporation

Recent Developments

  • In 2022, The University of Texas MD Anderson Cancer Center Researchers developed an ultrasound-guided cancer immunotherapy platform that generates systemic antitumor immunity and improves the therapeutic efficacy of immune checkpoint blockade. The findings from the preclinical study were published in Nature Nanotechnology.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Microbubbles/Ultrasound Contrast Agents Market size was valued at USD 1.87 billion in 2022 and is poised to grow from USD 1.94 billion in 2023 to USD 2.66 billion by 2031, growing at a CAGR of 4.00% during the forecast period (2024-2031). 

The major players covered in the microbubble contrast media market , while GE Healthcare is committed to providing a broad comprehensive portfolio of CM products that help meet your patient and procedural needs across a multitude of modalities. 'General Electric Company', 'Bracco Imaging S.p.A.', 'Lantheus Holdings, Inc.', 'Daiichi Sankyo Company, Limited', 'Bayer AG', 'Fujifilm Holdings Corporation', 'Sanofi S.A.', 'Siemens Healthineers AG', 'Guerbet Group', 'nanoPET Pharma GmbH', 'MBI Co., Ltd.', 'Trivitron Healthcare', 'Unilife Corporation', 'PTW Freiburg GmbH', 'Esaote SpA', 'Mindray Medical International Limited', 'Samsung Electronics Co., Ltd.', 'Shimadzu Corporation', 'Philips Healthcare', 'Canon Medical Systems Corporation', 'In 2022, The University of Texas MD Anderson Cancer Center Researchers developed an ultrasound-guided cancer immunotherapy platform that generates systemic antitumor immunity and improves the therapeutic efficacy of immune checkpoint blockade. The findings from the preclinical study were published in Nature Nanotechnology.'

The use of microbubbles and ultrasound contrast agents in molecular imaging is further driven by the growing demand for targeted therapies and the need to monitor the status of the biomarker in the vascular endothelium. During the forecast period, the microbubbles/ultrasound contrast agents market is anticipated to expand due to advancements in ultrasound technologies, an increase in the demand for targeted diagnostic tools, the advantages of microbubbles/ultrasound contrast agents over traditional diagnostic tools, and an increase in the prevalence of chronic diseases.

In cardiology and radiology, microbubbles are utilized as blood-pool agents for contrast ultrasound imaging. They are now being recognized for their potential as targeted agents for molecular imaging. Using ligand molecules that bind to disease-related molecular markers, microbubbles can be made functional. Monitoring the biomarker status of vascular endothelium, visualizing tumor vasculature, and imaging inflammation and ischemia-reperfusion injury zones and thrombi are all potential clinical applications of molecular imaging with microbubble-based ultrasound contrast agents.

Europe is anticipated to be dominant in the microbubbles/ultrasound contrast agents market. The growth of the microbubbles/ultrasound contrast agents market in North America and Europe is driven by an increase in the geriatric population, an increase in the incidence and prevalence of chronic diseases, a well-established healthcare infrastructure, an increase in the cost of research and development, an increase in the adoption of advanced technologies, and higher healthcare expenditure in the regions. India and China are expected to dominate the microbubbles/ultrasound contrast agents market in Asia-Pacific during the forecast period due to their large patient bases, rising awareness, increased government efforts to improve public health, and developed healthcare infrastructure. Due to the increasing investments made by market participants in these regions, it is anticipated that the market for microbubbles/ultrasound contrast agents will expand during the forecast period.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Microbubbles/Ultrasound Contrast Agents Market

Report ID: SQMIG35H2055

$5,300
BUY NOW GET FREE SAMPLE